This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: April 30th, 2012 - April 30th, 2013
This activity was developed for physicians and other healthcare professionals practicing in a managed care environment.
Upon completion of this activity, the participant will be able to:
- Explain the impact of key data presented at ASH 2011 on payers and providers in the treatment and management of myelofibrosis
- Identify patient- or disease-associated factors, as well as economic factors that may impact the choice of a therapeutic agent to formulate a management strategy for the treatment of myelofibrosis
- Evaluate the association between improvement in symptoms of myelofibrosis and the benefit this provides for minimizing the overall burden of healthcare costs
Physician Credit Designation
The Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical Learning Institute, Inc. and the Center of Excellence Media, LLC. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Planners’ and Managers’ Disclosures
- William J. Wong, MD, MLI Reviewer, has nothing to disclose.
- Linda M. Ritter, PhD, Medical and Scientific Director, has nothing to disclose.
- John Fox, MD, has nothing to disclose.
- Michael J. Mauro, MD, has received research support from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis.
The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for any agent discussed in this program should be inferred.
Estimated time to complete activity: 1.5 hours